Phase 1/2 interim data on moderna's mrna-3927, an investigational mrna therapy for propionic acidemia, published in nature

Cambridge, ma / accesswire / april 3, 2024 / moderna, inc. (nasdaq:mrna) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of mrna-3927, an investigational mrna therapy for propionic acidemia (pa), has been published in nature. "we are excited to share the first published clinical data utilizing an mrna therapy for intracellular protein replacement," said kyle holen, m.d.
MRNA Ratings Summary
MRNA Quant Ranking